HIV drug resistance profile of HIV-1 CRF 01_AE protease and integrase coding regions in HIV infected Cambodian patients failing LPV-based 2nd line antiretroviral regimen

作者：Janin Nouhin, Sopheak Ngin, Sreymom Ken, Vara Ouk, Olivier Ségéral, Kimlay Chea, Kerya Phon, Jean‐François Delfraissy, Eric Nerrienet · 发表于：BMC Proceedings · 年份：2011 · DOI：10.1186/1753-6561-5-s1-p89 · 被引用次数：1 · 研究领域：HIV/AIDS drug development and treatment、HIV/AIDS Research and Interventions、HIV Research and Treatment

By the end of 2009, the number of HIV-1 infected patients on RTI-based 1 line and PI-based 2 line ARV regimen in Cambodia reached 34,000 and 1,500, respectively. We already reported good virological and immunological responses after 1 to 4 years in cohorts of patients on 1 line and more recently, among an Esther cohort of 70 patients after 2 years on LPVr-based 2 line regimen. However, emergence of LPV resistant associated mutations is becoming a major concern in low and middle income countries. This study aimed to describe the resistance pattern of both the protease (PR) and integrase (IN) coding regions in HIV-1 CRF01-AE infected patients failing LPV-based 2 line regimen in Cambodia. Analysis of the Protease and Integrase drug resistance genotyping of 95 HIV-1 strains infected patients presenting detectable viral load on LPV/r-based 2 line regimen in Cambodia. Lack of amplification in PR gene was observed for 18/95 presenting low viral load (median VL: 2.9Log 10 copies/ml [IQR: 2.8-3.4]). The 77 other CRF01_AE strains, harbored polymorphism mutation in position M36, H69 and L89 conferring possibly resistance to TPV/r. Forty-nine (median VL: 5Log 10 copies/ml [IQR: 4 - 5.5]) did not present any other PI associated resistance mutation. In contrast, 28 patients showed multiple resistances to PI. The median duration on LPV/r regimen was 34.5 months [IQR: 23.5 – 53.3] and the median VL was 5Log 10 copies/ml [IQR: 4.3-5.6]. Twenty-five patients were resistant to LPV/r (7 possibly...